We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Researchers from the The Institute of Cancer Research, London and Artios have identified a new class of drugs – POLQ inhibitors – which could have potential for patients with BRCA-mutated tumours.